Enhanced efficacy was seen with a combination of intraperitoneal STING agonist in combination with conventional carboplatin chemotherapy and anti-PD-1 checkpoint blockade in a model of high-grade serous ovarian cancer, a notoriously “cold” tumour site. Here, STING1 is linked to neoplasm.